We are analyzing https://link.springer.com/article/10.1007/bf01703109.

Title:
The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study | Annals of Hematology
Description:
One hundred and forty one patients were treated in a combined Eastern Cooperative Oncology Group and Southwest Oncology Group phase-III study evaluating low-dose cytarabine (LDAC) versus supportive therapy for the treatment of myelodysplastic syndrome (MDS). Patients were randomized to either cytarabine 10 mg/m2 subcutaneously BID or supportive therapy. Central pathology review was required. All patients were classified according to the FAB criteria for MDS. The overall concordance rate for the MDS subtype was 52%, and 25 patients were pathology exclusions, including 20 with AML. The overall response rate to a single cycle of LDAC was 32%, with 11% complete and 21% partial responses. The median duration of response was 5.9 months, with a range of 1.4–33.5 months. Responses were seen in all subtypes. Infections were more common in the LDAC arm. There was no difference in the time to progression or the overall survival for patients treated with LDAC or supportive therapy. The incidence of leukemic transformation was similar in both arms at 15%, but it differed according to the MDS subtype. Patients receiving LDAC had a decreased transfusion requirement after 3 months. There was a significant correlation between the degree of cytoreduction after receiving a single cycle of LDAC and survival. This survival difference was most marked in patients with the RAEB and RAEB-T subtypes. Although LDAC produced responses in all subtypes of the MDS, there was no effect on overall survival or transformation to AML. However, selected patients benefited from a single cycle of LDAC with durable responses. A cytoreductive effect appears to be required for a durable response. Future studies should include pathology review and must address the clinical and biological heterogeneity of MDS.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Insurance

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

google, scholar, myelodysplastic, syndromes, patients, article, analysis, cytarabine, leukemia, lowdose, study, ldac, acute, data, survival, access, myeloid, syndrome, mds, cancer, center, privacy, cookies, content, treatment, group, clinical, human, haematol, university, information, publish, research, search, bennett, oncology, therapy, randomized, response, responses, open, chemotherapy, blood, med, prognostic, hematol, medical, log, journal, hematology,

Topics {✒️}

french-american-british cooperative group phase-iii intergroup study high-dose cytosine arabinoside month download article/chapter low-dose cytosine arabinoside chronic myelodysplastic syndrome acute myeloid leukemia southwestern oncology group low-dose cytarabine low dose cytarabine recombinant human interleukin-3 chronic myelodysplastic syndromes related subjects leukemia intergroup study childrens research hospital privacy choices/manage cookies mississippi medical center full article pdf hematology article pennsylvania cancer center myelodysplastic syndrome european economic area scope submit manuscript decreased transfusion requirement bone marrow transplantation proposed revised criteris 13-cis retinoic acid generalized linear models long-term analysis refined chromosome analysis check access instant access /ii study conditions privacy policy central pathology review include pathology review myelodys-plastic disorders rochester cancer center longitudinal data analysis independent prognostic indicator accepting optional cookies article annals hematology aims cytoreductive effect appears dysmyelopoietic syndrome acute leukemia selected patients benefited versus supportive therapy journal finder publish article miller

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study
         description:One hundred and forty one patients were treated in a combined Eastern Cooperative Oncology Group and Southwest Oncology Group phase-III study evaluating low-dose cytarabine (LDAC) versus supportive therapy for the treatment of myelodysplastic syndrome (MDS). Patients were randomized to either cytarabine 10 mg/m2 subcutaneously BID or supportive therapy. Central pathology review was required. All patients were classified according to the FAB criteria for MDS. The overall concordance rate for the MDS subtype was 52%, and 25 patients were pathology exclusions, including 20 with AML. The overall response rate to a single cycle of LDAC was 32%, with 11% complete and 21% partial responses. The median duration of response was 5.9 months, with a range of 1.4–33.5 months. Responses were seen in all subtypes. Infections were more common in the LDAC arm. There was no difference in the time to progression or the overall survival for patients treated with LDAC or supportive therapy. The incidence of leukemic transformation was similar in both arms at 15%, but it differed according to the MDS subtype. Patients receiving LDAC had a decreased transfusion requirement after 3 months. There was a significant correlation between the degree of cytoreduction after receiving a single cycle of LDAC and survival. This survival difference was most marked in patients with the RAEB and RAEB-T subtypes. Although LDAC produced responses in all subtypes of the MDS, there was no effect on overall survival or transformation to AML. However, selected patients benefited from a single cycle of LDAC with durable responses. A cytoreductive effect appears to be required for a durable response. Future studies should include pathology review and must address the clinical and biological heterogeneity of MDS.
         datePublished:
         dateModified:
         pageStart:162
         pageEnd:168
         sameAs:https://doi.org/10.1007/BF01703109
         keywords:
            Low-dose cytarabine
            Myelodysplastic snydrome
            Hematology
            Oncology
         image:
         isPartOf:
            name:Annals of Hematology
            issn:
               1432-0584
               0939-5555
            volumeNumber:65
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:K. B. Miller
               affiliation:
                     name:Tufts New England medical Center Hospital
                     address:
                        name:Tufts New England medical Center Hospital, Boston
                        type:PostalAddress
                     type:Organization
               type:Person
               name:K. Kyungmann
               affiliation:
                     name:Dana-Farber Cancer Institute
                     address:
                        name:Dana-Farber Cancer Institute, Boston
                        type:PostalAddress
                     type:Organization
               type:Person
               name:F. S. Morrison
               affiliation:
                     name:University of Mississippi Medical Center
                     address:
                        name:University of Mississippi Medical Center, Jackson
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J. N. Winter
               affiliation:
                     name:Northwestern University Medical Center
                     address:
                        name:Northwestern University Medical Center, Chicago
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J. M. Bennett
               affiliation:
                     name:University of Rochester Cancer Center
                     address:
                        name:University of Rochester Cancer Center, Rochester
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R. S. Neiman
               affiliation:
                     name:Indiana University Medical Center
                     address:
                        name:Indiana University Medical Center, Indianapolis
                        type:PostalAddress
                     type:Organization
               type:Person
               name:D. R. Head
               affiliation:
                     name:St. Jude's Childrens Research Hospital
                     address:
                        name:St. Jude's Childrens Research Hospital, Memphis
                        type:PostalAddress
                     type:Organization
               type:Person
               name:P. A. Cassileth
               affiliation:
                     name:University of Pennsylvania Cancer Center
                     address:
                        name:University of Pennsylvania Cancer Center, Philadelphia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. J. O'Connell
               affiliation:
                     name:Mayo Clinic
                     address:
                        name:Mayo Clinic, Rochester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study
      description:One hundred and forty one patients were treated in a combined Eastern Cooperative Oncology Group and Southwest Oncology Group phase-III study evaluating low-dose cytarabine (LDAC) versus supportive therapy for the treatment of myelodysplastic syndrome (MDS). Patients were randomized to either cytarabine 10 mg/m2 subcutaneously BID or supportive therapy. Central pathology review was required. All patients were classified according to the FAB criteria for MDS. The overall concordance rate for the MDS subtype was 52%, and 25 patients were pathology exclusions, including 20 with AML. The overall response rate to a single cycle of LDAC was 32%, with 11% complete and 21% partial responses. The median duration of response was 5.9 months, with a range of 1.4–33.5 months. Responses were seen in all subtypes. Infections were more common in the LDAC arm. There was no difference in the time to progression or the overall survival for patients treated with LDAC or supportive therapy. The incidence of leukemic transformation was similar in both arms at 15%, but it differed according to the MDS subtype. Patients receiving LDAC had a decreased transfusion requirement after 3 months. There was a significant correlation between the degree of cytoreduction after receiving a single cycle of LDAC and survival. This survival difference was most marked in patients with the RAEB and RAEB-T subtypes. Although LDAC produced responses in all subtypes of the MDS, there was no effect on overall survival or transformation to AML. However, selected patients benefited from a single cycle of LDAC with durable responses. A cytoreductive effect appears to be required for a durable response. Future studies should include pathology review and must address the clinical and biological heterogeneity of MDS.
      datePublished:
      dateModified:
      pageStart:162
      pageEnd:168
      sameAs:https://doi.org/10.1007/BF01703109
      keywords:
         Low-dose cytarabine
         Myelodysplastic snydrome
         Hematology
         Oncology
      image:
      isPartOf:
         name:Annals of Hematology
         issn:
            1432-0584
            0939-5555
         volumeNumber:65
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:K. B. Miller
            affiliation:
                  name:Tufts New England medical Center Hospital
                  address:
                     name:Tufts New England medical Center Hospital, Boston
                     type:PostalAddress
                  type:Organization
            type:Person
            name:K. Kyungmann
            affiliation:
                  name:Dana-Farber Cancer Institute
                  address:
                     name:Dana-Farber Cancer Institute, Boston
                     type:PostalAddress
                  type:Organization
            type:Person
            name:F. S. Morrison
            affiliation:
                  name:University of Mississippi Medical Center
                  address:
                     name:University of Mississippi Medical Center, Jackson
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J. N. Winter
            affiliation:
                  name:Northwestern University Medical Center
                  address:
                     name:Northwestern University Medical Center, Chicago
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J. M. Bennett
            affiliation:
                  name:University of Rochester Cancer Center
                  address:
                     name:University of Rochester Cancer Center, Rochester
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R. S. Neiman
            affiliation:
                  name:Indiana University Medical Center
                  address:
                     name:Indiana University Medical Center, Indianapolis
                     type:PostalAddress
                  type:Organization
            type:Person
            name:D. R. Head
            affiliation:
                  name:St. Jude's Childrens Research Hospital
                  address:
                     name:St. Jude's Childrens Research Hospital, Memphis
                     type:PostalAddress
                  type:Organization
            type:Person
            name:P. A. Cassileth
            affiliation:
                  name:University of Pennsylvania Cancer Center
                  address:
                     name:University of Pennsylvania Cancer Center, Philadelphia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. J. O'Connell
            affiliation:
                  name:Mayo Clinic
                  address:
                     name:Mayo Clinic, Rochester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Annals of Hematology
      issn:
         1432-0584
         0939-5555
      volumeNumber:65
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Tufts New England medical Center Hospital
      address:
         name:Tufts New England medical Center Hospital, Boston
         type:PostalAddress
      name:Dana-Farber Cancer Institute
      address:
         name:Dana-Farber Cancer Institute, Boston
         type:PostalAddress
      name:University of Mississippi Medical Center
      address:
         name:University of Mississippi Medical Center, Jackson
         type:PostalAddress
      name:Northwestern University Medical Center
      address:
         name:Northwestern University Medical Center, Chicago
         type:PostalAddress
      name:University of Rochester Cancer Center
      address:
         name:University of Rochester Cancer Center, Rochester
         type:PostalAddress
      name:Indiana University Medical Center
      address:
         name:Indiana University Medical Center, Indianapolis
         type:PostalAddress
      name:St. Jude's Childrens Research Hospital
      address:
         name:St. Jude's Childrens Research Hospital, Memphis
         type:PostalAddress
      name:University of Pennsylvania Cancer Center
      address:
         name:University of Pennsylvania Cancer Center, Philadelphia
         type:PostalAddress
      name:Mayo Clinic
      address:
         name:Mayo Clinic, Rochester, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:K. B. Miller
      affiliation:
            name:Tufts New England medical Center Hospital
            address:
               name:Tufts New England medical Center Hospital, Boston
               type:PostalAddress
            type:Organization
      name:K. Kyungmann
      affiliation:
            name:Dana-Farber Cancer Institute
            address:
               name:Dana-Farber Cancer Institute, Boston
               type:PostalAddress
            type:Organization
      name:F. S. Morrison
      affiliation:
            name:University of Mississippi Medical Center
            address:
               name:University of Mississippi Medical Center, Jackson
               type:PostalAddress
            type:Organization
      name:J. N. Winter
      affiliation:
            name:Northwestern University Medical Center
            address:
               name:Northwestern University Medical Center, Chicago
               type:PostalAddress
            type:Organization
      name:J. M. Bennett
      affiliation:
            name:University of Rochester Cancer Center
            address:
               name:University of Rochester Cancer Center, Rochester
               type:PostalAddress
            type:Organization
      name:R. S. Neiman
      affiliation:
            name:Indiana University Medical Center
            address:
               name:Indiana University Medical Center, Indianapolis
               type:PostalAddress
            type:Organization
      name:D. R. Head
      affiliation:
            name:St. Jude's Childrens Research Hospital
            address:
               name:St. Jude's Childrens Research Hospital, Memphis
               type:PostalAddress
            type:Organization
      name:P. A. Cassileth
      affiliation:
            name:University of Pennsylvania Cancer Center
            address:
               name:University of Pennsylvania Cancer Center, Philadelphia
               type:PostalAddress
            type:Organization
      name:M. J. O'Connell
      affiliation:
            name:Mayo Clinic
            address:
               name:Mayo Clinic, Rochester, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Tufts New England medical Center Hospital, Boston
      name:Dana-Farber Cancer Institute, Boston
      name:University of Mississippi Medical Center, Jackson
      name:Northwestern University Medical Center, Chicago
      name:University of Rochester Cancer Center, Rochester
      name:Indiana University Medical Center, Indianapolis
      name:St. Jude's Childrens Research Hospital, Memphis
      name:University of Pennsylvania Cancer Center, Philadelphia
      name:Mayo Clinic, Rochester, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(69)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.03s.

LINK . SPRINGER . COM {}